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Abstract
Background: Tuberculosis (TB) is a major public health problem globally. Little is known about TB incidence in adolescents
who are a proposed target group for new TB vaccines. We conducted a study to determine the TB incidence rates and risk
factors for TB disease in a cohort of school-going adolescents in a high TB burden area in South Africa.
Methods: We recruited adolescents aged 12 to 18 years from high schools in Worcester, South Africa. Demographic and
clinical information was collected, a tuberculin skin test (TST) performed and blood drawn for a QuantiFERON TB Gold assay
at baseline. Screening for TB cases occurred at follow up visits and by surveillance of registers at public sector TB clinics over
a period of up to 3.8 years after enrolment.
Results: A total of 6,363 adolescents were enrolled (58% of the school population targeted). During follow up, 67 cases of
bacteriologically confirmed TB were detected giving an overall incidence rate of 0.45 per 100 person years (95% confidence
interval 0.29–0.72). Black or mixed race, maternal education of primary school or less or unknown, a positive baseline
QuantiFERON assay and a positive baseline TST were significant predictors of TB disease on adjusted analysis.
Conclusion: The adolescent TB incidence found in a high burden setting will help TB vaccine developers plan clinical trials in
this population. Latent TB infection and low socio-economic status were predictors of TB disease.
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Introduction
Tuberculosis (TB) is a major public health problem globally
with 8.8 million cases being diagnosed in 2010 of whom 1.1
million died [1]. Incidence rates start to rise in adolescents and
precede a peak in adulthood in developing countries [2]. New TB
vaccines are being developed as part of the strategy to combat TB
and adolescents are a proposed target for such vaccines [3].
However, relatively little has been published on the incidence of
TB in adolescents. Two clinical trials of BCG in adolescents
provide limited incidence data [4,5] and studies on TB in
adolescents have focused on the clinical features of TB in this
group [6–9]. A latent TB infection prevalence of about 50% has
been reported for the population described in this report and for
another adolescent group from South Africa [10,11].
Since there is currently no immune correlate of protection
against TB, end points based on evidence of tuberculosis disease
will be needed for new TB vaccine efficacy trials and these would
need to be specific to optimize efficacy assessments [12,13].
Knowledge of TB incidence rates based on specific clinical disease
features will be crucial for planning the size of efficacy trials.
We conducted a study to determine the TB incidence rate and
risk factors for TB disease in a cohort of school-going adolescents
in a high TB burden area in South Africa. Other publications on
this study population include: 1) An examination of risk factors for
latent TB infection based on the tuberculin skin test (TST) and
QuantiFERON TB Gold (in-tube) (QFT) assay results at
enrolment [11] 2) A comparison of the predictive value of baseline
TST and QFT for TB disease during follow-up [14] 3) The
determination of the predictive value of a QFT conversion for TB
disease in a subset of participants who underwent extended follow
up [15] and 4) The measurement of the prevalence of TB disease
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at enrolment and the value of certain screening tests for detecting
TB (manuscript under review).
Materials and Methods
Study Setting
The study took place in the town of Worcester and surrounding
villages, approximately 100 kilometres from Cape Town, South
Africa. The total population of the municipal area from which the
adolescents were drawn was estimated as 146,101 by the
Department of Health in 2005, the year when recruitment started.
According to the national Census of 2001, there were 21,056
adolescents aged 12–18 (14% of the total population) in the
municipal area targeted and 83% of these adolescents were
attending schools. The study area was a subset of the municipal
area and consisted of a major town and two villages within this
area. Based on the Census 2001 population data for the municipal
area and high school attendance data of 10,492 in the study area,
we estimated that there were 12,641 adolescents aged 12–18 years
in the study area in total.
Study Participants
All adolescents aged 12–18 years attending all 11 publicly
funded high schools in the study area were approached to
participate. The very few small private schools in the study area
were not approached.
Study Procedures
At enrolment, demographic, socio-economic and clinical
information were collected through interview of parents and the
participating adolescent [11]. Blood was taken for QuantiFER-
ONH TB Gold In-tube (Cellestis, Victoria, Australia) (QFT) and a
tuberculin skin test (TST) was administered at baseline. Those
with previous or current TB or with a previous severe reaction to
TST did not have a TST performed, in order to prevent severe
allergic reactions. The reading of the tuberculin skin test took
place between 48 and 96 hours after administration, slightly longer
than the more commonly used limit of 72 hours but there are data
and recommendations which suggest that this is acceptable
[16,17]. A trained nurse examined each adolescent for a BCG
scar. Participants were screened for TB at baseline (the overall
number of cases diagnosed will be reported here but details of
these cases are the subject of another publication (4 above)).
All participants enrolled were scheduled for follow up visits
after two years which included a blood draw for QFT and the
administration of a TST. About half underwent three monthly
visits prior to this which included six monthly QFTs and annual
TSTs to compare follow up strategies while the other half were
seen only at baseline and two year visit (details of the
comparison of the two follow up strategies will be reported
separately). At follow up visits, those with new symptoms or a
new household contact compared to baseline, a converted TST
($10 mm increase from baseline) or converted QFT (change
from negative to positive) were investigated for active TB. In
addition, passive surveillance was conducted of TB clinic and
hospital admission registers in the area for any TB cases
diagnosed between visits. Investigation for TB involved the
collection of two sputum samples for smear examination on two
separate occasions. For persons with at least one positive smear,
a culture was performed, a chest x-ray done and an HIV test
offered. The radiologist’s report on the chest –x ray was used to
classify chest-x-ray findings.
Study Duration
Enrolment started in July 2005 and was completed in April
2007. Follow up was completed at the end of February 2009.
Owing to financial constraints, about 10% of the two year visits
were performed one to two months short of two years towards the
end of the study. Follow up was thus continued for a minimum of
22 months. Those completing their two year visits were followed
up passively until all other subjects had completed their two year
visits. This gave a maximum follow up time of 3.8 years.
Definitions
The protocol definition of a TB case was a diagnosis of
intrathoracic tuberculosis with either two positive sputum smears
and/or one single positive sputum culture (‘‘bacteriologically
confirmed TB’’). However, data on all individuals placed on TB
treatment by a physician were recorded (‘‘all TB’’). A chest x-ray
consistent with active tuberculosis was defined as ‘‘compatible with
TB’’ - this included pleural effusions. An ‘‘abnormal chest x-ray’’
was defined as any abnormality judged to be evidence of active
disease including TB and evidence of old/previous disease.
Sample Size Determination
Those agreeing to participate determined the sample size. Based
on routine TB programme data, we expected to find an incidence
rate of bacteriologically confirmed TB of 0.5 per 100 person years.
With an anticipated sample size of 6,500 and an expected
incidence rate of bacteriologically confirmed TB of 0.5 per 100
person years over two years of follow up, we expected to yield a
95% confidence interval (precision) of approximately 0.4 to 0.6/
100 person years.
Data Analysis and Statistical Considerations
Data were captured in a Microsoft Access database, and
analysed with STATA version 11.0 (Statacorp, Texas, USA). Data
were verified and validated prior, during and after data entry
according to a data entry standard operating procedure.
Total person-time for TB incidence analysis was calculated from
date of enrolment to date of the last visit of the last participant, TB
diagnosis or death, whichever occurred first. Those lost to follow-
up were assigned the duration of time to when last seen plus half
the duration between that visit and the next missed visit.
Univariate analysis was performed on demographic, socio-
economic and clinical characteristics examining their association
with ‘‘bacteriologically confirmed TB’’. Hazard rates with 95%
confidence intervals were calculated using poisson regression. The
design effect was accounted for during statistical analysis, the
clusters being the 11 schools from which the participants were
enrolled. Kappa statistics were used to evaluate collinearity
amongst the potential risk factor variables to avoid over-matching
in building models for multivariate analysis. The risk factors for
TB disease were analysed in a multivariate Cox regression model
using the statistically significant variables (p,0.05) on univariate
analysis to determine adjusted hazard ratios.
Ethics
This study was approved by the Faculty of Health Sciences
Human Research Ethics Committee of the University of Cape
Town. Written informed consent was obtained from the parents of
adolescents and assent obtained from adolescents.
Results
6,363 adolescents were enrolled (58% of 10,492 registered at
local schools and 50% of the estimated total adolescent population
TB Incidence in Adolescents
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of 12,641 in the study area). Enrolment by school ranged from
22.2% to 74.4%. 5203 (81.8%) participants completed their two
year visits, 660 (10.4%) withdrew, 11 (0.2%) died and 489 (7.7%)
were lost to follow up prior to their two year visit. 84% (1,939/
2,310) of participants who met the criteria for investigation
underwent the required tests.
Participant Baseline Profile
The demographic and clinical profile of participants at
enrolment is shown in Table 1. There was a slight predominance
of females (54%) in the study population compared to the source
population data supplied by the Department of Education (50%
were female). There was a greater proportion of younger
adolescents (#15 years) than those .15 years since there were
fewer adolescents in the higher school grades. BCG scars were
faded in some adolescents so it was difficult to be sure about their
presence in certain instances. Twenty one cases of TB were
diagnosed at baseline of whom 19 were culture positive.
Profile of Incident Cases
There were 87 TB incident cases detected during follow up, 67
(77.0%) of whom met the protocol definition (bacteriologically
confirmed TB). A profile of the cases is set out in Table 2. Most
incident cases (61 or 70%) were culture positive and most (63 or
72%) had chest –x-ray changes suggestive of tuberculosis. All those
diagnosed with TB (87) were offered HIV testing, 61 (70.1%) of
whom accepted and of whom only one (1.6%) was found to be
positive.
Incidence Rates
Incidence rates using varying definitions of what constitutes a
TB case are set out in Table 3. This resulted in a range of
incidence rates from 0.30 to 0.59/100 person years. The highest
annual number of cases occurred during the second year of follow
up i.e. 33 (49%) of bacteriologically confirmed cases (Table 4). Ten
additional cases (15%) were detected through surveillance after the
two year visit. The rates of disease in the successive years of follow
up were not statistically significantly different from each other.
Incidence rates varied widely amongst the different schools from 0
to 2% cumulative incidence and 0 to 0.9/100 person years
incidence rates suggesting the possibility of micro-epidemics in
certain schools but confidence intervals were wide making these
data difficult to interpret. Eight bacteriologically confirmed cases
were diagnosed within 6 months of enrolment. If we consider the
possibility that these may have been cases missed at baseline and
were in fact prevalent cases, then the incidence rate based on the
bacteriologically confirmed cases drops to 0.40 per 100 person
years (pyrs) (95% CI 0.27–0.58). Incidence rates by TST
induration size were as follows: ,5 mm–0.20/100 pyrs (95% CI
0.11–0.38), 5–9 mm–0.17/100 pyrs (95% CI 0.04–0.71), 10–
14 mm–0.40/100 pyrs (95% CI 0.30–0.53) and $15 mm–1.18/
100 pyrs (95% CI 0.77–1.81). There was thus a trend of increasing
incidence with increasing induration with an induration of
$15 mm being significantly higher than the other categories.
Risk Factors for TB
An unadjusted univariate analysis of the relationship between
demographic, socio-economic and clinical variables, and TB
incidence using hazard ratios is set out in Table 1. A comparison
between those having three monthly follow up versus those with
just a baseline and two year visit showed no statistically significant
difference in incidence rates and is not shown in this analysis. In
unadjusted analysis, statistically significant risk factors for bacte-
riologically confirmed TB were being of black or mixed race origin
compared to being of white or Indian origin, maternal education
primary school or less and maternal education unknown, current
or prior household contact, a positive TST and a positive QFT.
Absence of a BCG scar was of borderline statistical significance.
These risk factors were considered for fitting in a Cox regression
model. We could not include ethnic group since there were no
cases in the reference group. Maternal education primary school
or less and maternal education unknown were combined into a
single variable. BCG coverage in South Africa is high at more than
95%. We therefore assumed that those with an ‘‘unknown/
unsure’’ scar were BCG vaccinated and these were grouped with
those with a definite scar present for the Cox regression analysis.
The following comparisons were tested for collinearity using the
kappa statistic: TST versus QFT, prior or current household TB
contact versus TST and prior or current household TB contact
versus QFT since all three were potential indicators of TB
exposure. Only the TST and QFT outcomes were found to be
collinear (percentage agreement 85.0%, kappa 0.7). They could
thus not be fitted into a model simultaneously. In adjusted analysis
(Table 5), absence of a BCG scar, maternal education primary
school or less, or unknown and a positive QFT were statistically
significant predictors of TB disease while prior household contact
was not. When QFT was replaced with TST in the model (not
shown), the TST was also a significant predictor with a hazard
ratio of 2.4 (95% CI 1.2–4.8). In this model, maternal education
primary school or less or unknown remained a predictor of TB
disease (hazard ratio 1.9, 95% CI 1.1–3.1) but not absence of a
BCG scar. When we defined the presence of a BCG scar strictly
and excluded those with scar ‘‘unknown/not sure’’ and repeated
the Cox regression (N = 4061), BCG scar and QFT were both only
of borderline significance, hazard ratios 1.7 (95% CI 0.9–3.2,
p = 0.06) and 1.7 (95% CI 1.0–2.9, p = 0.07) respectively while
maternal education of primary school or less or unknown
remained significant at hazard ratio 1.4 (95% CI 1.0–1.9,
p = 0.04). With this reduced dataset, when TST replaced QFT
in the model, only TST remained significant 2.4 (95% CI 1.3–4.3,
p = 0.007).
Discussion
We found a TB incidence rate of 0.45/100 person years of TB
in school-going adolescents in a high burden area. The clinical
profile of TB cases was mainly of the adult type: most were
confirmed bacteriologically and most had evidence of chest x-ray
abnormalities. Significant predictors of TB disease during follow
up included demographic, socio-economic and latent TB infection
variables. While it was notable that most incident cases occurred in
the second year of follow up, differences across the years were not
statistically significant.
The British MRC trial in adolescents aged 14.5–15.5 years
conducted from 1950–1970 showed an annual incidence rate of
0.25 per 100 in the first five years of the study in the BCG
unvaccinated group who were TST negative at enrolment with a
similar rate in those with a TST of .15 mm at enrolment [5].
This rate was similar to the 0.2 per 100 found in the TST negative
group in our study but not to those with an induration of $15 mm
who had a significantly higher incidence rate than those with a
negative TST. One important difference was that the adolescents
in our study had mostly been vaccinated with BCG at birth. Those
who were BCG vaccinated in the MRC trial had a lower rate of
0.04 per 100 but had been vaccinated in adolescence as part of the
trial so cannot be compared to the adolescents in our study.
Children who were aged 7–14 years of age in the Brazilian BCG
TB Incidence in Adolescents
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revaccination trial had rates of 0.03 per 100 person years [4],
much lower than in our study. This is probably due to the
difference in burden of TB in each country given that South Africa
(981/100,000) has a much higher overall incidence rate of TB
than Brazil (85/100,000) [1]. The TB incidence rate found in this
study is similar to that based on routine TB control programme
data in our study area. It was also similar but not identical to the
rate reported in a prior publication on this cohort (0.43/100
person years) due to that analysis focusing on a subset of the cohort
Table 1. Unadjusted analysis of risk factors for TB disease for bacteriologically confirmed TB cases.




100 pyrs* Hazard ratio 95% CI**#
Gender
Female 3,458 (54.3%) 45 0.55 1.7 0.5–5.3
Male (ref***) 2,905 (45.7%) 22 0.33 1.0 -
Age (years)
.15 2,760 (43.4%) 31 0.49 1.2 0.7–2.0
#15 (ref) 3,603 (56.6%) 36 0.42 1.0 -
Racial group
Black and mixed race 5,921 (93.1%) 67 0.48 Perfect predictor
Indian/white (ref) 442 (6.9%) 0 0.00
Parent income: classified on at least one parent’s income
,R4000/month 5,313 (83.5%) 62 0.50 2.3 0.6–8.7
.R4000/month (ref) 1,050 (16.5%) 5 0.22 1.0 –
Maternal highest education level
Primary school or less 1,893 (29.8%) 28 0.63 1.7 1.1–2.7
High school or more (ref) 3,482 (54.7%) 24 0.29 1.0 –
Unknown 988 (15.5%) 15 0.68 1.6 1.1–2.4
Paternal highest education level
Primary school or less 849 (13.3%) 12 0.59 1.4 0.6–3.0
High school or more(ref) 2,042 (32.1%) 15 0.31 1.0 –
Unknown: 3,472 (54.6%) 40 0.50 1.3 0.8–2.0
BCG scar
Absent 1,813 (28.5%) 24 0.59 1.5 1.0–2.2
Present (ref) 2,565 (40.3%) 22 0.36 1.0 –
Unknown (Not sure) 1,985 (31.2%) 21 0.46 1.0 0.6–1.6
Current or prior TB household contact
Yes 1,728 (27.2%) 31 0.77 2.3 1.1–4.8
No (ref) 4,635 (72.8%) 36 0.45 1.0 –
Previous TB
Yes 639 (10.0%) 14 0.93 1.5 0.7–3.2
No (ref) 5,709 (89.7%) 73 0.55 1.0 –
Unknown 15 (0.3%) 0 0.00 0
TST status at baseline
TST positive ($5 mm) 3,115 (49.0%) 44 0.61 3.0 1.4–6.5
TST negative (ref) 2,456 (38.6%) 12 0.20 1.0 –
TST unknown**** 702 (12.4%) 11 0.68 1.6 0.7–3.7
QFT status at baseline
QFT positive 3,233 (50.8%) 48 0.65 2.4 1.4–4.2
QFT Negative (ref) 2,804 (44.1%) 17 0.27 1.0 –
QFT indeterminate or unknown 326 (5.1%) 2 0.21 0.5 0.05–4.7
*pyrs – person years.
**95% CI = 95% confidence interval.
#adjusted for the design effect.
***ref – reference.
****Those with previous or current TB or with a previous severe reaction to TST did not have a TST performed, in order to prevent severe allergic reactions.
doi:10.1371/journal.pone.0059652.t001
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(5244) where participants with both baseline TST and QFT results
were required for analysis [14].
The profile of cases in our study was typical of adult type
disease, a finding similar to that shown in a different adolescent
population in South Africa by Weber et al [6]. They reviewed the
TB diagnosis records of 324 adolescents aged 10–18 years and
found 78% to have had bacteriological evidence of disease and
94%, intra-thoracic lesions on chest x-ray. They found 10% with
evidence of primary TB whereas we found none, but their lower
age limit was younger (10 years) than in our study (12 years). Very
few extra-thoracic cases of TB were detected in our study similar
to the 6% of cases reported as extra-thoracic by Weber et al [6].
At least 87% of cases in our study had abnormal chest x-rays
confirming the microbiological findings of evidence of TB disease.
The choice of TB case definition resulted in some variation in
the TB incidence calculation. Given the need for a specific
definition in a clinical trial setting to avoid undermining efficacy
estimates [12,13], careful consideration needs to be given to the
endpoint case definition for clinical trials. Unlike the pediatric
setting where the disease is pauci-bacillary and where reaching
consensus on endpoints for infant trials has been difficult [18],
most cases in adolescents were microbiologically confirmed
suggesting that the use of a highly specific definition is feasible.
We have shown previously that latent TB infection as
demonstrated by a positive TST or QFT is associated with a
higher risk of progressing to TB disease [14]. The analysis in this
paper shows specifically that this relationship persists even when
confounders are controlled for. The treatment of latent TB
infection with isoniazid as prophylaxis (IPT) is not standard of care
in South Africa for HIV negative persons over the age of 5. Fifty
percent of adolescents as shown in our study and a higher
proportion of adults are latently infected [19]. Implementation of
IPT in South Africa would thus be very resource intensive. The
benefits of IPT in high TB burden settings for HIV negative
adolescents and adults are not clear. A recent large study of IPT in
miners in South Africa showed benefit in reducing the risk of TB
only while isoniazid was being taken but this benefit was lost when
treatment was completed [20]. The university ethics committee
which approved this study did not require the provision of INH
prophylaxis in adolescents who were latently infected.
The fact that the absence of a BCG scar was shown to be linked
to a higher risk of developing TB is surprising given the high






Number of cases Total 87 (100%) 67 (100%)
Site of disease Intrathoracic Extra-thoracic 84 (97%) 3 (3%) 67 (100%) 0 (0%)
Smear and culture results Smear and culture positive Smear negative, culture positive 42 (48%) 19 (22%) 42 (63%) 15 (22%)
Smear positive, culture negative 9 (10%) 8 (12%)
Smear and culture negative 13 (15%) 0 (0%)
Smear positive, culture not done 2 (2%) 2 (3%)
Smear negative, culture not done 2 (2%) 0 (0%)
Chest x-rays Compatible with TB: 63 (72%) 51 (76%)
Abnormal but not typical of TB 8 (9%) 6 (9%)
Compatible with old/healed TB 5 (6%) 4 (6%)
Normal 3 (3%) 1 (1%)
Not done/missing/no report 8 (9%) 5 (7%)
doi:10.1371/journal.pone.0059652.t002
Table 3. TB incidence rates using different case definitions.
Cases
Cumulative incidence (%) (Mean
2.3 years of follow up) N = 6,363
Incidence rate (per 100 pyrs*)
(95% CI**)***. pyrs = 14,786
All 87 1.36 0.59 (0.36–0.96)
Bacteriologically confirmed 67 1.05 0.45 (0.29–0.72)
Culture confirmed 61 0.96 0.41 (0.23–0.71)
Chest x-ray compatible with TB 63 0.99 0.43 (0.27–0.68)
Culture positive and chest x-ray compatible with TB 45 0.71 0.30 (0.17–0.54)
Culture positive and abnormal chest x-ray
(includes those compatible with TB)
54 0.85 0.37 (0.21–0.62)
Bacteriologically confirmed TB and chest x-ray compatible with TB 51 0.80 0.34 (0.21–0.56)
Bacteriologically confirmed TB and abnormal chest x-ray 61 0.96 0.41 (0.27–0.64)
*pyrs = person years.
**95% CI = 95% confidence interval.
***adjusted for the design effect.
doi:10.1371/journal.pone.0059652.t003
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population burden of TB in a country with a high coverage of
BCG (.95%) [21]. The benefit was only found when QFT was
part of the multivariate model but not when it was replaced with
TST nor when the presence of the BCG scar was strictly classified
and those whose scars were classified as ‘‘unsure’’ were excluded
from analysis. There should therefore be caution in interpreting
this finding and the absence of a BCG scar may not be indicative
of an absent immune response to BCG or indicative of not
receiving BCG. A study in India showed no difference in leukocyte
migration levels in young BCG vaccinated children between those
who developed a BCG scar and those who did not [22]. A recent
editorial referencing this and other studies also commented on the
lack of correlation between adaptive cellular immune responses
and BCG scar formation, and the authors recommend further
studies to clarify the differences between those with and those
without a BCG scar [23].
The fact that a low or unknown level of maternal education is
linked to progression to TB disease is interesting and requires
further investigation but surprisingly, parental low income was not,
given the known relationship between poverty and TB. Also
unexpected was the fact that household TB contact was not shown
to be a statistically significant risk factor for TB on adjusted
analysis. This may be because the study was not sufficiently
powered to show this relationship or due to household contact
being very common in this high burden setting. Black or mixed
race was a perfect predictor of the onset on TB. It is likely that this
association is linked to underlying socio-economic factors given
South Africa’s history [24] but this could not be properly tested in
multivariate analysis.
The TB incidence rates measured in this study show that large
sample sizes will be needed to power clinical trials evaluating the
efficacy of new TB vaccines in adolescents. For a vaccine trial
expected to show a vaccine efficacy of 60% at a 95% significance
level and with 80% power, a study duration of 2 years with
completion rate of 82% and cumulative incidence of bacteriolog-
ically confirmed TB of 1.05% in the unvaccinated group (as found
in this study [Table 3]), a sample size of 6400 participants would
be needed in a study with a 1:1 vaccine to placebo ratio.
This study has a number of limitations: HIV testing was not
done routinely because it was believed that this population would
not have a high prevalence of HIV. This decision was vindicated
by the finding that among participants diagnosed with TB, only
one was confirmed to be HIV positive with most agreeing to be
tested. Besides the data on gender distribution, no other data was
available on those not enrolled in the study. A proportion was
older than 18 but there was no exact data on this. In addition,
many refused to participate due to fear of blood draws. Our results
may thus be biased because of differences between the enrolled
and unenrolled populations but we do not believe that this was
major given the main reason given for refusal to participate and
given that others were not eligible due to their age.
The selections of schools as the source of participants
introduced a cluster effect and this produced incidence rates with
wider confidence intervals than would have been produced by a
purely random sample. While the majority of participants who met
the criteria for investigation for TB underwent the required tests,
some (371) did not which may have resulted in the actual number
of cases being underestimated. However, we believe that the
surveillance system would in most instances have eventually picked
up cases missed in this way. Hypothetically, given a cumulative
incidence of 1.05%, 4 TB cases could have been missed in this
group. Smear negative, culture positive TB cases diagnosed early
in year one might possibly be cases missed at baseline given that
smears were the main method of investigation. In a clinical trial
setting using more rigorous screening methods, such cases would
have been picked up at baseline and the rates in this study may
therefore be an overestimate of incidence relative to what might be
expected in a clinical trial. An endpoint committee was not used
for case classifications. The case classifications were purely data
driven with chest x-ray findings being based only on the
radiologists reports. Given that most data items were clear-cut,
we do not believe that an endpoint committee would have
classified cases significantly differently.
Finally, this study represents the burden of disease at schools
only. Adolescents not at school are likely to be located in poorer
environments and the TB incidence rate in the total population of
adolescents is likely to be higher.
In conclusion, the incidence rates in school-going adolescents in
a high burden TB setting ranged from 0.30 to 0.59 per 100 person
years using varying case definitions. These data will be essential for
the planning of clinical trials of new TB vaccines in adolescents.
Table 4. Annual incidence rate by year of study up to
February 2009 for bacteriologically confirmed TB* (n = 6,363).




Yr 1 6363 23 6,245 0.37 (0.19–0.72)
Yr 2 5784 33 5,557 0.59 (0.40–0.88)
Yr 3 4884 11 2,762 0.40 (0.21–0.75)
Total 67 14,786 0.45(0.29–0.72)
*No cases were reported in year 4 of follow up so this rate has not been
included in the table.
**pyrs = person years.
***95% CI = 95% confidence interval.
****adjusted for the design effect.
doi:10.1371/journal.pone.0059652.t004
Table 5. Adjusted analyses of risk factors for bacteriologically confirmed cases of TB (N = 6,036).
Variables Hazard Ratio P. z 95% CI*#
BCG scar absent 1.5 0.04 (1.0–2.1)
Positive baseline QuantiFERON 2.0 0.02 (1.2–3.3)
Mother’s education primary school or less, or unknown 1.8 0.01 (1.2–2.7)
Prior or current household TB contact 1.7 0.15 (0.8–3.9)
*95% CI = 95% confidence interval.
#adjusted for the design effect.
doi:10.1371/journal.pone.0059652.t005
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The risk factors shown to be associated with TB will be useful in
estimating TB rates in various risk groups in these clinical trials.
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